Shares of Novo Nordisk climbed 4.5% on Wednesday after the Danish pharmaceutical giant reported a stronger-than-expected ...

CagriSema is a fixed-dose combination of cagrilintide, a long-acting amylin analogue, and semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), that works by decreasing hunger and ...

The U.S. Food and Drug Administration has approved Supernus Pharmaceuticals' drug-device combination to treat movement-related symptoms of Parkinson's disease, the drugmaker said on Tuesday.

REDEFINE 1 is a 68-week efficacy and safety trial investigating subcutaneous CagriSema (a fixed dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg) compared to the individual ...

Novo Nordisk CEO Lars Fruergaard Joergensen in December during a presentation of a new production site. The company's latest attempt at a weight loss drug, CagriSema, matched the bar set by a ...

CagriSema – a combination of Novo Nordisk's GLP-1 agonist semaglutide with dual amylin and calcitonin receptor agonist cagrilintide – achieved a 20.4% reduction in weight in the REDEFINE 1 ...

Amycretin affects the same two targets as a Novo drug called cagrisema that recently missed expectations in a Phase 3 trial, ...

In recent years, the pharmaceutical industry has undergone significant changes in the focus of its innovation, research and ...

CagriSema is a combination of the GLP-1 agonist semaglutide, the ingredient found in Novo’s Ozempic and Wegovy, and cagrilintide, which mimics two hormones, amylin and calcitonin, that also help ...

CagriSema is a fixed-dose combination of a long-acting amylin analogue, cagrilintide 2.4 mg and Wegovy. The two molecules promote weight loss by suppressing hunger, enhancing feelings of fullness ...

Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently approved medicine, Zepbound, but didn’t cleanly surpass it in late-stage ...